Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) CEO Carole Ben-Maimon acquired 18,050 shares of the stock in a transaction dated Wednesday, November 11th. The shares were bought at an average cost of $2.77 per share, for a total transaction of $49,998.50. Following the acquisition, the chief executive officer owned 386,326 shares in the company, valued at $1,070,123.02. The trade was a 4.90% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Larimar Therapeutics Price Performance
Shares of LRMR stock traded up $0.32 during trading on Friday, reaching $3.02. The company had a trading volume of 2,531,459 shares, compared to its average volume of 1,257,255. Larimar Therapeutics, Inc. has a one year low of $1.91 and a one year high of $6.42. The firm’s 50 day simple moving average is $2.93 and its two-hundred day simple moving average is $3.76. The company has a market capitalization of $313.72 million, a PE ratio of -1.55 and a beta of 0.73.
Wall Street Analysts Forecast Growth
LRMR has been the topic of a number of research analyst reports. Wedbush reiterated an “outperform” rating on shares of Larimar Therapeutics in a research note on Tuesday, November 10th. Wall Street Zen lowered shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Leerink Partners assumed coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Larimar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $10.33.
Read Our Latest Research Report on Larimar Therapeutics
Institutional Trading of Larimar Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP lifted its holdings in shares of Larimar Therapeutics by 9.1% during the third quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock worth $7,005,000 after buying an additional 183,496 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Larimar Therapeutics in the third quarter worth $268,000. Blue Owl Capital Holdings LP increased its position in Larimar Therapeutics by 0.3% during the third quarter. Blue Owl Capital Holdings LP now owns 9,923,904 shares of the company’s stock worth $31,707,000 after acquiring an additional 32,147 shares during the period. AIGH Capital Management LLC bought a new position in Larimar Therapeutics during the third quarter worth $5,911,000. Finally, WINTON GROUP Ltd acquired a new position in Larimar Therapeutics during the 2nd quarter valued at $160,000. Institutional investors and hedge funds own 91.92% of the company’s stock.
Key Larimar Therapeutics News
Here’s some of the latest news about LRMR:
- Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
- Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Recommended Stories
- Five stocks we like better than Larimar Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
